top of page


Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing targeted small molecule therapeutics to treat serious diseases and conditions by leveraging the microbiome’s role in human health. Axial is a scientific leader focusing on the interface between the microbiome and the human body. Rooted in a decade of ground-breaking research, Axial employs unique and proprietary preclinical models to identify and validate targets and generate drug candidates designed to address the microbiome-driven pathology of a particular disease.


The company is advancing a pipeline of Microbiome-Inspired Therapeutics® for diseases with significant unmet patient need, including autism and Parkinson’s disease, and is also pursuing preclinical discovery of gut-targeted therapies in liver disease and oncology. Axial’s lead product candidate is AB-2004, a molecular therapeutic in Phase 2 clinical trials for the treatment of irritability in children with autism. The company is also developing AX-5006 for Parkinson’s Disease with a clinical trial planned to begin in 2024.

At Axial, we are committed to ensuring the safety and security of our community and potential candidates.  Job applicants should be aware of job offer scams perpetrated through the use of the Internet and social media platforms. Axial is not currently hiring and we urge you to exercise caution and verify the authenticity of the communications before proceeding. Please do not hesitate to reach out to us directly at for confirmation before engaging further with any recruitment-related communications.

Open Positions:

Currently there are no open positions.

Check back for more information about career opportunities at Axial.

bottom of page